Most antiviral strategies act selectively on the virus replication machinery over that of the host, with the difference between host toxicity and antiviral activity determining efficacy. This can involve preferential binding to, or activation by, viral proteins over those of the host. The anti-HSV (herpes simplex virus) drug acyclovir (ACV) is a classic example that employs both strategies: ACV is activated only in HSV-infected cells by the initial phosphorylation by the herpes simplex virus type 1 (HSV-1)-specified thymidine kinase, and then the triphosphate form of ACV is preferentially used by the HSV-1-encoded polymerase over that of the host, resulting in DNA chain termination. While effective, viral genetic changes can result in modified structure or expression of the viral proteins involved, resulting in the development of antiviral resistance.
